Teva Stocks Surge on Positive Phase 2b Study Results
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) shares rose 17% following the announcement of successful Phase 2b study results for the investigational drug duvakitug, developed for the treatment of inflammatory bowel disease (IBD). The study, conducted in collaboration with Sanofi, met primary endpoints in patients with ulcerative colitis (UC) and Crohn's disease (CD), promising a new treatment option in a area with high unmet medical needs.
The RELIEVE UCCD study demonstrated that a significant portion of patients treated with duvakitug achieved clinical remission or an endoscopic response by week 14, compared to those receiving a placebo. The stock movement reflects investor optimism regarding the potential market impact of the drug, given the consistent treatment effect across subgroups. Teva’s shares reacted to the news with a 17% increase.
Dr. Eric Hughes, Teva’s Head of Global R&D and Chief Medical Officer, expressed confidence regarding the study results and the potential benefits for patients living with IBD. Dr. Houman Ashrafian, Head of R&D and Executive Vice President at Sanofi, also emphasized the potential of duvakitug to be a differentiated drug for IBD patients. Both companies praised their collaborative efforts in the development of the drug.
Duvakitug was generally well-tolerated, with no significant safety concerns identified. Rates of treatment-related adverse events were similar between the drug and placebo groups, and all reported adverse events were below 5%. This safety profile, along with the efficacy data, positions Teva and Sanofi to move forward to the next phase of clinical development.
Although the efficacy and safety of duvakitug have yet to be evaluated by any regulatory agency, the positive Phase 2b results have laid the groundwork for further clinical studies. Detailed results from the study are expected to be presented at a scientific forum in 2025, which will provide a clearer picture of the drug’s potential impact on the market and patient care.
Investors will closely monitor the progress of duvakitug as Teva and Sanofi continue their collaboration aimed at addressing the urgent need for new treatment options for those affected by ulcerative colitis and Crohn's disease.